Article not rated

Vol. 23 - Num. 91

Evidence based Pediatrics

Bronchodilators in bronchiolitis: should we reassess their selective use?

Carlos Ochoa Sangradora, Álvaro Gimeno Díaz de Ataurib

aServicio de Pediatría. Complejo Asistencial de Zamora. Zamora. España.
bServicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.

Correspondence: C Ochoa. E-mail: cochoas2@gmail.com

Reference of this article: Ochoa Sangrador C, Gimeno Díaz de Atauri Á. Bronchodilators in bronchiolitis: should we reassess their selective use? Rev Pediatr Aten Primaria. 2021;23:317-20.

Published in Internet: 20-09-2021 - Visits: 1146

Abstract

Authors’ conclusions: compared to guidelines‐guided strategy, treating infants with viral bronchiolitis using the phenotypic‐guided bronchodilator therapy strategy is a more cost‐effective strategy, because it involves a lower probability of hospital admission at lower total treatment costs. Randomized controlled trials using biomarkers to stratify patients most likely to respond to bronchodilators are necessary.

Reviewers’ commentary: the available information does not seem sufficient to make changes to the current recommendations in acute bronchiolitis management. There is still need for a predictive model that allows to identify potential responders to bronchodilators, as well as a clinical trial with a sufficient sample size to estimate the effectiveness of the strategy of its selective use.

Keywords

Bronchiolitis Bronchodilators Costs and cost analysis.

 

Comments

This article has no comments yet.